OncoMatch/Clinical Trials/NCT06257394
Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
Is NCT06257394 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Dasatinib(Sprycel) arm and Non-Dasatinib(Sprycel) arm for acute lymphoblastic leukemia, pediatric.
Treatment: Dasatinib(Sprycel) arm · Non-Dasatinib(Sprycel) arm — Very high-risk acute lymphoblastic leukemia
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: BCR fusion with ABL1 (Philadelphia chromosome-positive t(9;22)(q34;q11))
Philadelphia chromosome-positive t(9;22)(q34;q11)
Required: TCF3 fusion with HLF (E2A-HLF translocation-positive)
E2A-HLF(Hepatic Leukemia Factor) translocation-positive
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06257394 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require BCR?
Yes, BCR fusion with ABL1 (Philadelphia chromosome-positive t(9;22)(q34;q11)) is a required biomarker for enrollment.
Does this trial require TCF3?
Yes, TCF3 fusion with HLF (E2A-HLF translocation-positive) is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 19 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify